| Traditional Chinese patent medicine has a long history of clinical use.It is widely used,with characteristics of stable nature,accurate efficacy,small side effects,easy to take and carry,etc.However,due to historical reasons,there are many practical problems in the clinical application of Chinese patent medicine.Carefully combing preclinical research of Chinese patent medicine,systematically evaluating relevant literature of post-marketing research,analyzing relevant information of adverse drug reactions,combining the latest progress of modern medical research and clinical experience of experts in related fields,and formulating consensus of experts in clinical application have become the key to guide clinicians to use traditional Chinese patent medicine more accurately,safely and widely.Yangxinshi Tablets,developed and produced by Qingdao Growful Pharmaceutical Co.,Ltd.,Shanghai Pharma,is a preparation of Chinese patent medicine(SDFA Approval No.Z37021102)with independent intellectual property rights,included in Pharmacopoeia of the People's Republic of China(2015 edition).Sponsored jointly by Professional Committee on Cardiovascular Diseases,Professional Committee on Interventional Cardiology and Professional Committee on Cardiac Rehabilitation of World Federation of Chinese Medicine Societies(WFCMS),Cardiovascular Disease Branch of Chinese Association of Chinese Medicine,Professional Committee on Cardiovascular Diseases of Chinese Association of Integrative Medicine,and Cardiovascular Professional Committee of Chinese Association for Research and Advancement of Chinese Medicine,experts of traditional Chinese medicine,western medicine and integrated traditional Chinese and western medicine in cardiovascular diseases were organized and they spent nearly 2 years to systematically review and summarize the formulation basis,pharmacological effect,clinical research and safety data of Yangxinshi Tablets,discussing and drafting Consensus of Experts on Clinical Application of Yangxinshi Tablets in Treatment of Coronary Heart Disease.The author further interprets the core content of the consensus. |
